XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue $ 36,161 $ 60,827
License Revenue [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 6,000 22,590
Development Revenue [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 3,891 11,762
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 22,590
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 95 32
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 1,529 5,148
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]    
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]    
Total revenue $ 2,032 $ 5,819